ArticleThe Journal of allergy and clinical immunology2011
Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies.
Article in The Journal of allergy and clinical immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Purine nucleoside phosphorylase deficiency induces p53-mediated intrinsic apoptosis in human induced pluripotent stem cell-derived neurons.Scientific reports · 2022Article
- Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing.Stem cell research & therapy · 2020Review
- Review
- Establishment and characterization of induced pluripotent stem cells (iPSCs) from central nervous system lupus erythematosus.Journal of cellular and molecular medicine · 2019Article
- Exome and genome sequencing for inborn errors of immunity.The Journal of allergy and clinical immunology · 2016Review
- Article
- hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine.Journal of cellular and molecular medicine · 2016Review
- Integrated analysis of mRNA, microRNA and protein in systemic lupus erythematosus-specific induced pluripotent stem cells from urine.BMC genomics · 2016Article
- Flow Cytometry, a Versatile Tool for Diagnosis and Monitoring of Primary Immunodeficiencies.Clinical and vaccine immunology : CVI · 2016Review
- Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells.International journal of molecular sciences · 2015Review
- Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies.Frontiers in immunology · 2015Review
- Differential role of nonhomologous end joining factors in the generation, DNA damage response, and myeloid differentiation of human induced pluripotent stem cells.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Review
- Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status.Stem cell research & therapy · 2013Article
- Article
- Article
- The role of induced pluripotent stem cells in research and therapy of primary immunodeficiencies.Current opinion in immunology · 2012Review
- Advances in basic and clinical immunology in 2011.The Journal of allergy and clinical immunology · 2012Review
- The promise of human induced pluripotent stem cells in dental research.Stem cells international · 2012Article
- Immunological applications of stem cells in type 1 diabetes.Endocrine reviews · 2011Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 10 institutions in 6 countries.
Funding
Abstract
backgroundThe novel ability to epigenetically reprogram somatic cells into induced pluripotent stem cells (iPSCs) through the exogenous expression of transcription promises to revolutionize the study of human diseases.
objectiveHere we report on the generation of 25 iPSC lines from 6 patients with various forms of primary immunodeficiencies (PIDs) affecting adaptive immunity, innate immunity, or both.
methodsPatients' dermal fibroblasts were reprogrammed by expression of 4 transcription factors, octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2), Krueppel-like factor 4 (KLF4), and cellular myelomonocytosis proto-oncogene (cMYC), by using a single excisable polycistronic lentiviral vector.
resultsiPSCs derived from patients with PIDs show a stemness profile that is comparable with that observed in human embryonic stem cells. After in vitro differentiation into embryoid bodies, pluripotency of the patient-derived iPSC lines was demonstrated by expression of genes characteristic of each of the 3 embryonic layers. We have confirmed the patient-specific origin of the iPSC lines and ascertained maintenance of karyotypic integrity.
conclusionBy providing a limitless source of diseased stem cells that can be differentiated into various cell types in vitro, the repository of iPSC lines from patients with PIDs represents a unique resource to investigate the pathophysiology of hematopoietic and extrahematopoietic manifestations of these diseases and might assist in the development of novel therapeutic approaches based on gene correction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.